Perrigo (NYSE:PRGO) Releases FY 2025 Earnings Guidance

Perrigo (NYSE:PRGO) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.700-2.80 for the period, compared to the consensus earnings per share estimate of 2.960. The company issued revenue guidance of -, compared to the consensus revenue estimate of $4.4 billion.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on PRGO shares. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $20.00 price objective (down from $32.00) on shares of Perrigo in a research report on Thursday. Wall Street Zen raised Perrigo from a “hold” rating to a “buy” rating in a report on Sunday, October 26th. Jefferies Financial Group lowered their price objective on Perrigo from $27.00 to $23.00 and set a “hold” rating on the stock in a research report on Monday, October 27th. Weiss Ratings restated a “sell (d)” rating on shares of Perrigo in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group set a $20.00 target price on Perrigo in a research report on Thursday. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $22.50.

Perrigo Stock Down 2.7%

Shares of Perrigo stock traded down $0.41 during trading on Thursday, reaching $14.70. The company’s stock had a trading volume of 2,918,873 shares, compared to its average volume of 1,629,666. Perrigo has a 1-year low of $14.46 and a 1-year high of $30.93. The company has a market cap of $2.02 billion, a price-to-earnings ratio of -25.20 and a beta of 0.42. The company has a quick ratio of 1.24, a current ratio of 2.32 and a debt-to-equity ratio of 0.81. The company has a 50-day simple moving average of $21.70 and a two-hundred day simple moving average of $24.55.

Perrigo (NYSE:PRGO) last posted its earnings results on Wednesday, November 5th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.05. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.10 billion. Perrigo had a negative net margin of 1.86% and a positive return on equity of 9.09%. The business’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.81 EPS. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS. As a group, equities analysts forecast that Perrigo will post 2.56 earnings per share for the current year.

Perrigo Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 16th. Stockholders of record on Friday, November 28th will be paid a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 7.9%. The ex-dividend date is Friday, November 28th. Perrigo’s dividend payout ratio (DPR) is presently -305.26%.

Insider Activity

In related news, EVP Abigail Lennox purchased 1,255 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was acquired at an average price of $22.41 per share, for a total transaction of $28,124.55. Following the acquisition, the executive vice president directly owned 1,255 shares of the company’s stock, valued at $28,124.55. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Eduardo Guarita Bezerra acquired 3,000 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was acquired at an average cost of $22.74 per share, for a total transaction of $68,220.00. Following the completion of the purchase, the chief financial officer owned 48,949 shares in the company, valued at $1,113,100.26. The trade was a 6.53% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 10,118 shares of company stock worth $232,699. 0.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Perrigo

Several hedge funds and other institutional investors have recently modified their holdings of PRGO. Ion Asset Management Ltd. raised its position in Perrigo by 34.7% in the second quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock valued at $102,007,000 after purchasing an additional 983,727 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Perrigo by 126.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after buying an additional 647,982 shares during the period. State Street Corp lifted its holdings in shares of Perrigo by 9.5% in the 2nd quarter. State Street Corp now owns 7,340,323 shares of the company’s stock worth $196,134,000 after purchasing an additional 637,678 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Perrigo by 52.5% during the second quarter. Ameriprise Financial Inc. now owns 1,308,334 shares of the company’s stock worth $34,959,000 after acquiring an additional 450,247 shares during the last quarter. Finally, Quantinno Capital Management LP increased its stake in shares of Perrigo by 149.9% in the second quarter. Quantinno Capital Management LP now owns 527,588 shares of the company’s stock valued at $14,097,000 after purchasing an additional 316,466 shares during the period. 95.91% of the stock is owned by institutional investors and hedge funds.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.